Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
TMO$680.00-26.03(-3.69%)Thermo Fisher Scientific Announces Quarterly Dividend5:00:04 PM ETWPM$131.25-0.25(-0.19%)Wheaton Precious Metals Announces Third Quarter 2026 Results and Record Year-to-Date Production, Sales Volume, Revenue, Earnings and Cash Flow5:00:00 PM ETANTUPDATE 1-A&O Shearman's $1.1 billion AI plan builds on law firms' tech investments4:51:58 PM ETLRCX$193.83-27.45(-12.41%)BUZZ-Chip firm Lam Research rises after announcing $25 bln stock buyback4:50:28 PM ETNVDA$181.90-18.39(-9.18%)Stock Market Today, Nov. 5: Nvidia Slides on AI Chip Selloff as Election Uncertainty Weighs4:49:38 PM ETPTGX$135.26-8.19(-5.71%)Protagonist Therapeutics Q3 revenue surges on Takeda payments4:48:48 PM ETWFC$84.52-2.94(-3.36%)Wells Fargo & Company (WFC) Presents at BancAnalysts Association of Boston Conference 2026 Transcript4:45:03 PM ETTSLA$340.62-44.56(-11.57%)Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms4:43:33 PM ETBAC$49.79-1.85(-3.58%)MEDIA-BofA Rejigs Global Credit Trading Businesses To Boost Liquidity - Bloomberg News4:43:14 PM ETMNKD$3.65-0.29(-7.36%)MannKind Q3 revenue rises on royalty gains4:43:13 PM ETDIS$116.70-2.28(-1.92%)Disney employees use a town hall meeting to press management for details on a possible next round of layoffs4:42:35 PM ETMSFT$529.56-26.45(-4.76%)Microsoft Q3 Earnings: The Only Top AI Hyperscaler Generating Positive FCF (Rating Downgrade)4:42:33 PM ETNVDA$181.90-18.39(-9.18%)Thursday's Final Takeaways: Mortgage Rates Continue Decline, NVDA Chips to China4:34:31 PM ETNVDA$181.90-18.39(-9.18%)Nvidia Plunges 9% as AI Selloff Wipes Out $2.3 Trillion | Closing Bell4:32:42 PM ETKLAC$130.50-19.15(-12.80%)KLA Declares Regular Cash Dividend4:30:14 PM ETMU$669.53-125.93(-15.83%)Micron Announces Board of Directors Retirement4:30:06 PM ETMU$669.53-125.93(-15.83%)Micron Announces Board of Directors Retirement4:30:00 PM ETKO$95.60-0.28(-0.29%)DRIVX Moves Toward Final Presale Stage, Unveils Fleet Expansion and Transparent Vesting Strategy4:19:08 PM ETCRWD$218.00-22.98(-9.54%)Why CrowdStrike and cybersecurity stocks got crunched in Thursday's rout4:12:00 PM ETNVDA$181.90-18.39(-9.18%)Nvidia's Huang is asked to brief Congress on reported Chinese spy relationship4:09:56 PM ETLRCX$193.83-27.45(-12.41%)Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend4:05:00 PM ETSKHY$125.30-17.78(-12.43%)Why SK Hynix Plunged Today4:01:39 PM ETNVDA$181.90-18.39(-9.18%)Is Nvidia Still a Millionaire-Maker Stock?3:51:00 PM ETTSLA$340.62-44.56(-11.57%)SpaceX and Tesla Stock Plunges Have Wiped About $450 Billion in Value Since the Midterms. Is It Time to Buy?3:43:35 PM ET

MNKD · NASDAQ

MannKind Corporation

$3.65 -0.29 (-7.24%)

Company overview

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company also promotes Thyquidity to adult and pediatric endocrinologists and other healthcare providers for the treatment of hypothyroidism. MannKind has a license and collaboration agreement with United Therapeutics Corporation and an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. Incorporated in 1991, MannKind Corporation is headquartered in Westlake Village, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.2B
Employees
403
Headquarters
Danbury, CA
Website
mannkindcorp.com
CEO
Michael E. Castagna
Listed
July 28, 2004
P/E
-47.22
Dividend yield
0.00%

Company financials

Revenue
$361M
Gross profit
$274M
Operating income
$13.4M
EBITDA
$28.5M
Net income
-$23.9M
EPS
-$0.08
Total assets
$744M
Total debt
$437M
Gross margin
75.96%
Net margin
-6.63%
Earnings yield
-2.12%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

2.713.193.674.144.62
MNKD 1D NASDAQ O3.86H4.05L3.80C3.93+0.20 (+5.36%)Vol4.06M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
MNKDMannKind Corporation Stock news MannKind Q3 revenue rises on royalty gains Reuters
MNKDMannKind Corporation Stock news BRIEF-MannKind Q3 Basic EPS USD -0.07 Reuters
MNKDMannKind Corporation Press release MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
MNKDMannKind Corporation Press release MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 GlobeNewswire
MNKDMannKind Corporation Stock news This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Benzinga
MNKDMannKind Corporation Press release MannKind to Participate in the Chardan Healthcare Conference GlobeNewswire
MNKDMannKind Corporation Press release MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) GlobeNewswire
MNKDMannKind Corporation Stock news MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum MarketBeat
MNKDMannKind Corporation Stock news Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule Benzinga
MNKDMannKind Corporation Press release MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management GlobeNewswire
MNKDMannKind Corporation Press release MannKind to Present at Upcoming Investor Conferences GlobeNewswire
MNKDMannKind Corporation Stock news FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH Zacks Investment Research
MNKDMannKind Corporation Stock news MannKind: New Approvals Majorly Increase MannKind's Prospects Seeking Alpha
MNKDMannKind Corporation Stock news MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript Seeking Alpha
MNKDMannKind Corporation Stock news MannKind Q2 Earnings Call Highlights MarketBeat
MNKDMannKind Corporation Stock news Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics Zacks Investment Research
MNKDMannKind Corporation Stock news MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates Zacks Investment Research
MNKDMannKind Corporation Press release MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
MNKDMannKind Corporation Stock news MannKind (NASDAQ:MNKD) Shares Gap Up – Still a Buy? Defense World
MNKDMannKind Corporation Stock news FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease Benzinga
See more
FAQ

Questions about MannKind Corporation

What does MannKind Corporation do?
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company also promotes Thyquidity to adult and pediatric endocrinologists and other healthcare providers for the treatment of hypothyroidism. MannKind has a license and collaboration agreement with United Therapeutics Corporation and an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. Incorporated in 1991, MannKind Corporation is headquartered in Westlake Village, California.
What is MNKD's market cap?
MannKind Corporation (MNKD) is a listed stock with a live quote. The latest market cap on this page is $1.2B.
Where is MannKind Corporation headquartered?
MannKind Corporation is headquartered in Danbury, CA.
How do I get MNKD news from the API?
Call GET /v1/news?tickers=MNKD. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does MNKD news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MNKD, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the MNKD price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs